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Is Hypertonic Saline Superior to Mannitol in Reducing Cerebral Edema? 
Cerebral edema is a potentially life threatening complication that can arise from any acute 
neurological insult. The brain is encased in a closed skull and relies on fluid level to maintain a 
“balance”. Alexander Monro hypothesized that the blood circulating in the cranium was of 
constant volume at all times and his hypothesis was supported by experiments performed by 
Kelli. This became known as the Monro-Kelli doctrine, or hypothesis. An increase in one should 
cause a decrease in one or both of the remaining two.  Specifically, the Monro-Kelie hypothesis 
says that “the total bulk of three elements (inside the skull) the brain 1400 ml, cerebral spinal 
fluid (CSF) 150 ml and blood 150 ml must remain constant” (Jha, S. 2003). When the brain 
experiences a traumatic injury, rupture of aneurysm, mass or stroke, the skull cannot allow for 
the additional volume. If the brain, blood volume or CSF continues to rise, this will increase 
intercranial pressure (ICP) and reduce CSF from circulating. This will cause the brain to lose the 
capability to compensate leading to cerebral edema and the complications that develop. Urgent 
intervention is required to stop the cascade of events to prevent herniation and death. Surgical 
intervention is typically required to alleviate intercranial pressure; however medical management 
is still a very important component in controlling cytotoxic and/or vasogenic edema.  
Cytotoxic edema results from apoptosis and/or cellular injury. Intracellular trapping of 
sodium causes engorgement of the cell leading to apoptosis and release of sodium into the 
parenchyma. Vasogenic edema may be a secondary insult as it results from the breakdown of 
endothelial junctions of the blood-brain barrier (BBB). This breakdown allows proteins and 
intravascular fluids to enter the extracellular space. Both cytotoxic and vasogenic edema may 
result from traumatic brain injury, stroke, aneurysm rupture or brain tumors.  
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Traumatic brain injury (TBI) occurs in over 1.7 million people annually and is a 
contributing factor in 30.5% of all injury related deaths in the nation. Adults aged 75 years and 
older have the highest rates of TBI-related hospitalization and death. Unfortunately, 77.2% of 
those will die as a result of their injury. Non traumatic strokes are a close second affecting 
roughly 795,000 people annually.  Broken down that means every 40 seconds in the United 
States someone will have a stroke (www.cdc.gov/traumaticbraininjury). Spontaneous 
intracerebral hemorrhage (ICH) is a neurologic emergency that accounts for about 10-20% of all 
strokes and has a 30 day mortality rate of 35-52%. Only 21% of ICH patients are expected to 
recover at 6 months (Fernando D. Testai, Venkatesh, 2008). Finally, brain tumors are diagnosed 
in roughly 200,000 people annually; 40,000 of those diagnosed have a primary brain tumor while 
the remaining result from metastasis to the brain. Brain tumors are the second leading cause of 
cancer death in males ages 20-29 and the fifth leading cause in females ages 20-39. There are 
over 120 different types of brain tumors; however, medical management is essentially the same 
for all (www.cancer.gov). Therefore, the patient’s outcome from a cerebral insult is directly 
related to the degree of injury and extent of edema that ensues.  
Mannitol, a sugar alcohol has been the gold standard for the treatment of cerebral edema 
for several decades; however hypertonic saline (HS) is quickly gaining momentum as an equal or 
perhaps superior alternative to mannitol.  The underlying principles of the medications are to 
reduce cerebral edema with a diuretic affect as well as renal vasodilation.  
The purpose of this study is to evaluate the effectiveness of each drug and attempt to 
answer the question “Is Hypertonic Saline Superior to Mannitol in Reducing Cerebral Edema?”  
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A systematic review of literature was conducted to evaluate if hypertonic saline (HS) is 
superior to mannitol in reducing cerebral edema. Based on The Campbell Collaboration the 
purpose of a systematic review is to summarize the best available research to answer a specific 
question. This requires integration of the results of numerous studies. The object is to evaluate 
the outcomes of pertinent research that can be duplicated by other facilities under the same 
circumstances. “A systematic review must have: Clear inclusion/ exclusion criteria, an explicit 
search strategy, systematic coding and analysis of included studies, and meta-analysis” when 
available (http://www.campbellcollaboration.org). 
An internet search was conducted utilizing MD Consult, MEDLINE, CINAHL and 
Google scholar search engines. Initially, studies pertaining to mannitol were completed.  The 
second search included hypertonic saline and other research articles pertaining to other 
modalities of medical therapy for cerebral edema. Studies were searched based on levels of 
evidence as established by the U.S. Preventative Services Task Force (USPSTF). The USPSTF 
has two methods for grading levels of confidence. This particular study employed the following 
evidence categories:  
I: Evidence obtained from a single randomised [sic - British spelling from the original] 
controlled trial or a meta-analysis of randomised controlled trials 
 
IIa: Evidence obtained from at least one well-designed controlled study without randomisation 
 
IIb: Evidence obtained from at least one well-designed quasi-experimental study [i.e., no 
randomization and use of existing groups] 
 
III: Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies, and case-control studies 
 
IV: Evidence obtained from expert committee reports or opinions and/or clinical experience of 
respected authorities (http://sophia.smith.edu/~jdrisko/rating_the_evidence.htm) 
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Over one hundred articles were assessed in regards to mannitol alone or in comparison to other 
medical therapies. Inclusion criteria for the articles was based on clinical and laboratory studies, 
credibility, sufficient quality, credentials of authors, and ability to replicate the study. Studies 
were not excluded based on surgical intervention along with conservative treatment methods. 
Since evidence based practice is dependent on remarkable research, certain standards must be 
acknowledged. The highest level of review includes systematic, double blind studies and cohort 
studies. Weaker papers include case studies and opinion articles. Therefore articles that failed to 
meet the criteria were excluded, which included foreign language, insufficient data, opinion 
based without evidence and/or the age of the paper. Although a few older articles were included 
based on results or offered pertinent information for the review. After careful analysis, fifty one 
articles were selected for examination. Based on USPSTF guidelines, twenty six of the articles 
were evidence category I, fourteen were category II, seven level III and four were level IV. 
While the goal was to obtain level I or II, the lesser qualifying papers were kept for significant 
findings in the conclusion. This paper will compare the findings between the “gold standard” 
mannitol to hypertonic saline based on criteria documented previously.  
  Despite mannitol being the standard treatment of ICP for the last few decades in reducing 
cerebral edema, optimal dosing for the medication nor the affects of the medication based on 
other factors such as age, sex, location of insult have been established. Mannitol is a cell 
impermeable non-toxic alcohol and its purpose is to drive water out of cells to decrease volume  
(Zolta, 2007).The mechanism of mannitol is poorly defined, but effects are proposed to be 
mediated by the reduction in CSF by reducing water volume, and viscosity by vasoconstriction 
that leads to reducing blood volume within the brain (Rabinstein, 2008). Reduction of volume 
prevents further infarct to brain tissue, which is vital to decrease morbidity and mortality.  
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 Findings in the mannitol group were included in all studies reviewed, with or without HS 
for comparison. The dosage of mannitol most studied was 20% concentration; however 15% 
concentrations were also noted in two of the studies. Human and animal models were included. 
The studies concentrated on intercranial hemorrhage, stroke and traumatic brain injury. However 
a few studies were included whereby intercerebral edema was secondary to another medical 
problem. The articles evaluated mannitol dosing and protocols versus superiority to other agents 
such as HS. The effects of mannitol manifests within 30 minutes of administration and is 
generally sustained for several hours. Continuous infusion or scheduled boluses are standard for 
treatment; however repeated boluses have shown to have a direct correlation with rebound 
increases of ICP (Damek, 2010). Early responses to mannitol were all favorable. The smallest 
study included a single case study and the largest involved multi-center with 1572 patients in 
China. Most notable in the Chinese study it was documented that patients had a 3x higher 
mortality/disability that underwent neurosurgery in conjunction with medical therapy (Wei & 
Huang, 2011).  One study found that reduction in ICP with mannitol was greater in patients with 
supratentorial ICH compared to infratentorial ICH (Meyer, 2010). Others described significant 
differences in dosing and outcomes after initial ICP reduction, but not after ICP reached a fixed 
level. Mannitol saturation was noted to be the cause of patient receiving no further benefit from 
treatment. Based on analysis of studies, more than thirty medications have been tested in the 
treatment of ICP with mannitol demonstrating the greatest benefit (Annals of Emergency 
Medicine, 2010); however higher doses were documented to lead to volume depletion, severe 
electrolyte abnormalities such as rebound cerebral HTN, hypernatremia, hyperkalemia, 
metabolic acidosis and renal failure. Electrolyte disturbances were most significant after three 
days of mannitol therapy, most notably sodium levels (Sushree, 2008).  
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A retrospective random cohort study conducted on traumatic brain injury included 171 patients 
that were given mannitol as part of treatment plan. Patients were given mannitol and/or 
turosemide. Results of acute kidney injury was documented in both group based on accumulative 
dosing. It was shown that mannitol was an independent risk factor for acute kidney injury in 
head trauma patients (Fang, 2010). 
A study published in the Neurologic Clinics documented the osmotic effect of mannitol 
was found to increase serum tonicity, which draws edema from cerebral parenchyma. This 
process takes 15 to 30 minutes, until gradients are established. Serum osmolarity should be at or 
around 320 mOsm to avoid adverse effects from treatment, which included hypovolemia, 
hyperosmolarity, and renal failure. If mannitol opens the BBB it can leak to surrounding tissues 
and augment vasogenic edema. Therefore mannitol should be tapered to prevent a rebound in 
edema and ICP. Adverse effects were most pronounced when mannitol was utilized for extended 
periods. 
Finally, mannitol and HS were compared in patients that had experienced traumatic brain 
injuries to reduce the inflammation associated with injury. Neutrophils and monocytes have been 
proven to exacerbate cerebral edema as they are toxic to delicate cerebral tissues. The body’s 
own response to send neutrophils and increased production of chemokines lead to further insult 
by inflammatory cells. Under microscopic evaluation of tissues, neutrophils traveled across the 
choroidal epithelial directly into the CSF. In TBI a combination of cytotoxic as well as vasogenic 
edema typically are seen. Studies demonstrated reactive oxygen species (ROS), inflammatory 
cytokines, endothelial growth factor and matrix metalloproteinases have all been identified as 
cause of BBB leakage after trauma. This dysfunction of the BBB progresses through a positive 
feedback loop, leading to further damage of the brain. Mannitol and HS were compared in the 
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treatment of cerebral edema that is a result of neuroinflammatory response to trauma. It was this 
author’s opinion mannitol was superior in the reducing ICP in patients with TBI. Hypertonic 
saline was theorized to reduce water and potentially edema; however there was evidence of 
worsening effect on endothelial cells (Zink, 2010).  
In contrast studies demonstrate HS administered in concentrations from 3% to 23.4%, 
also creates an osmotic force to pull fluid from the interstitial space of the brain parenchyma into 
the intravascular compartment thereby reducing intracerebral volume and ICP. This study found 
in researching the topic that hypertonic saline was shown to be more effective than mannitol in 
reducing ICP. Hypertonic saline was documented to have advantage over mannitol in 
hypovolemic and hypotensive patients. Furthermore, mannitol is contraindicated in hypovolemic 
patients because of its diuretic effects, whereas HS enhanced intravascular volume and 
potentially increase blood pressure, along with decreasing ICP. However, hypertonic saline was 
not associated with improved neurologic outcomes. Adverse effects of hypertonic saline 
administration included hypokalemia. In addition hyponatremia needs to be excluded before 
administration of HS to reduce the risk for central pontine myelinolysis. The outcomes were not 
significantly different in final results (Infanti, 2008).   
Hypertonic saline has not been shown to improve mortality benefits, yet another study 
with 65 subjects noted different results in patients with traumatic brain injury. HS was initiated 
pre-hospital and significant changes were documented in inflammatory and coagulation markers 
on every patient in the study. Relative to control, NS patients showed up to a 2-fold higher 
surface expression of CD62L, CD11b and CD66b on polymorphonuclear neutrophils (PMNs) 
and monocytes that persisted for 48-h. HSD blunted the expression of these cell-surface 
activation/adhesion molecules at all time-points to levels approaching control values. Admission 
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concentrations of endothelial-derived sVCAM-1 and sE-selectin were generally reduced in HSD 
patients. Circulating sL-selectin levels were significantly elevated at 12 and 48, but not 24 h 
post-resuscitation with HSD. TNF-α and IL-10 levels were elevated above control throughout the 
study period in all patients, but were reduced in HSD patients. Plasma sTF and D-D levels were 
also significantly lower in HSD patients, whereas sTM levels remained at control levels (Rhind 
& Crnko, 2010). The results support an important role utilizing HS for resuscitation in easing 
upregulation of leukocyte and endothelial cell inflammatory mediators, which may help alleviate 
secondary brain injury.   
 Hypertonic saline compounds may be more effective than mannitol because the 
hypertonicity expands intravascular volume and cardiac performance. Based on an older study 
from Qureshi and Suarez (2000) hypertonic saline was first documented in medical literature 
around 1919 by Weed and McKibben after injecting 30% saline solution in cats. Shrinkage was 
noted in the parenchyma in 15-30 minutes after administration. Further studies were completed 
in the 1950’s most frequently on animal models; however HS was not widely accepted or used 
for the purpose of reducing cerebral edema. Even though this study is old, it was included 
because it covered 34 years of research and the lack of response from the medical community 
over this time span in utilizing HS as a valid treatment option. Hypertonic saline was shown in 
the older study to have positive outcomes in animal models to prevent or reduce ICP when used 
in the initial resuscitation phase of treatment instead of standard fluid resuscitation such as 
normal saline as well. HS was proven to have a favorable effect on systemic and intercranial 
pressures. The caveat in this study was mannitol was shown to have longer duration of benefit 
than HS. Even though HS has been utilized in the treatment of cerebral edema for almost100 
years, the outcome was more research is still needed to be done to establish HS as a superior 
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treatment to mannitol in human subjects with specific dosing guidelines including bolus versus 
continuous infusion.  
Hypertonic saline (HS) dosing ranges from 3-23.4% in studies reviewed. As with 
mannitol, no definitive dosing has been established to prove greater efficacy over the other. 
However studies suggest even the lowest concentration of 3% HS was shown to be sufficient to 
reduce water in the brain, elevate mean arterial pressure, reduce ICP and improve cerebral 
perfusion by reducing edema (Liu, 2011).  
Solution Sodium mmol/l Osmolality 
0.9 NS 154 308 
Mannitol __ 1373 
3% Saline 513 1026 
7.5% 1283 2565 
23.4% 4004 8008 
Twenty six articles were reviewed with the objective to evaluate HS efficacy versus 
mannitol and other medications for the treatment of increased ICP. One article initially described 
a valuable study. Research literature was obtained on HS, mannitol and nine other treatment 
options for ICP over a 28 year period; however the design was not well documented and results 
were vague. The study was therefore not included in the review of literature. Studies include 
animal and human trials. Interestingly several of the HS studies did not list number of patients in 
the trial. The most significant study was a multicenter, randomized clinical trial with 5848 
patients over a three year period. A large pre-hospital intervention was initiated in the treatment 
of hypovolemic shock and traumatic brain injury. Resuscitation efforts began in the field with 
7.5% HS treatment. The results displayed a favorable outcome with pre-hospital treatment as 
well set a standard of care for the community.   
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Due to the lack of standardization with most appropriate treatment for ICP one study 
addressed the issue by asking neurointensivists choice of agent and dosing protocols. 
Interestingly 295 practitioners responded with an almost even split. HS was preferred by 54% & 
the remaining preferred mannitol. Some respondents did say they reserved HS for patients with 
refractory intracranial HTN. Results were not surprising; variations in opinions will make 
standardization difficult at best (Hays, 2011).  Many articles found no significant difference 
between mannitol and HS, but one that stood out with significant results was HS in reversal of 
transtentorial herniation. Sixty eight patients were included in the study and the results were 
quite significant. Seventy-six TTH events occurred in 68 patients admitted with intracerebral 
hemorrhage (n = 29), subarachnoid hemorrhage (n = 16), stroke (n = 8), brain tumor (n = 8), 
subdural hematoma (n = 5), epidural hematoma (n = 1), and meningitis (n = 1). In addition to 
23.4% saline, TTH management included hyperventilation (70% of events), mannitol (57%), 
propofol (62%), pentobarbital (15%), ventriculostomy drainage (27%), and decompressive 
hemicraniectomy (18%). Reversal of TTH occurred in 57/76 events (75%). Intracranial pressure 
decreased from 23 ± 16 mm Hg at the time of TTH to 14 ± 10 mm Hg at 1 hour (p = 0.002), and 
11 ± 12 mm Hg at 24 hours (p = 0.001) among 22 patients with intracranial pressure monitors. 
Reversal of TTH was predicted by a =5 mmol/L rise in serum sodium concentration (p = 0.001) 
or an absolute serum sodium of =145 mmol/L (p = 0.007) 1 hour after 23.4% saline. Adverse 
effects included transient hypotension in 13 events (17%); no evidence of central pontine 
myelinolysis was detected on post-herniation MRI (n = 18). Twenty-two patients (32%) survived 
to discharge, with severe disability in 17 and mild to moderate disability in 5. Treatment with 
23.4% saline was associated with rapid reversal of transtentorial herniation (TTH) and reduced 
intracranial pressure, and had few adverse effects. Outcomes of TTH were poor, but medical 
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reversal may extend the window for adjunctive treatments. Herniation has a significant mortality 
rate and the results show promise for the use of HS in this subgroup of patients (Neurology, 
2008). Mannitol and HS were evaluated along with hypothermia and hyperventilation in the 
treatment of traumatic brain injury. Mannitol was deemed satisfactory except for patients with 
compromised intravascular volume. The treatment of choice was the administration of 
hypertonic saline. Recent data suggest that an intravenous bolus of 23.4% saline, 30 mL, given 
over 10 to 15 minutes, may effectively reverse herniation and decrease ICP, with only transient 
hemodynamic repercussions (Neurologic Clinics, 2008).  
Another comparison between the two diuretics documented better outcomes with HS 
alone. Four randomized clinical trials have evaluated efficacy and safety of mannitol and side 
effects of same. It was shown that HS did not create life threatening side effects or rebound 
cerebral hypertension. It was proven to be a safer alternative to mannitol; however the number of 
patients in the study were not included (Infanti, 2008). Hypertonic saline was deemed to be a 
safe alternative in all but one study. No scientific documentation was offered to prove theory in 
this study that mannitol was a safer alternative to HS.  
Results of this study suggest there was no significance in onset of action between mannitol 
and HS. Mannitol while effective showed rebound increases in ICP and saturation. Meaning 
effectiveness stopped after a certain level of infusion. There were no statistically significant 
mortality differences between the two medications despite decreasing ICP. Hypertonic saline 
was shown to be superior in reducing short term morbidity especially in patients with herniation. 
HS actually reversed herniation in this study allowing the physician more time to intervene and 
potentially reduce mortality risk in this subgroup of patients. Hypertonic saline demonstrated 
specific physiological responses:  HSD blunted the expression of these cell-surface 
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activation/adhesion molecules at all time-points to levels approaching control values. Admission 
concentrations of endothelial-derived sVCAM-1 and sE-selectin were generally reduced in HSD 
patients. Circulating sL-selectin levels were significantly elevated at 12 and 48, but not 24 h 
post-resuscitation with HSD. TNF-α and IL-10 levels were elevated above control throughout the 
study period in all patients, but were reduced in HSD patients. Plasma sTF and D-D levels were 
also significantly lower in HSD patients, whereas sTM levels remained at control levels. No 
adverse effects noted with HS with exception to one study; however the study did not offer 
adequate documentation to back up the generalized statement. Mannitol however was associated 
with sometimes severe electrolyte disturbances, and rebound intracranial hypertension. Articles 
specific to electrolyte disturbances saw these changes within 96 hours of initiation of treatment. 
Mannitol has long been the standard of care in the treatment of cerebral edema and ICP 
despite nearly one hundred years of documentation that hypertonic saline is a safe alternative 
treatment option. Each article reviewed made very pertinent arguments, but HS was proven to be 
equally effective as mannitol without the life threatening side effects. Hypertonic saline is 
contraindicated in heart failure; however this subset of patients would still have the benefit of 
mannitol. Hypertonic saline was documented to reverse herniation, which has significant 
morbidity and mortality. By reversing herniation, it will afford the patient more time for potential 
recovery that would not otherwise be an option. 
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In summary, a large multi-center study would be recommended to support HS superiority 
to mannitol in these very complex patients. Guidelines should be established in regards to 
standardizing treatment protocols for both medications; specifically dosage, continuous infusion 
versus bolus and length of time medications will be administered for preeminent outcomes.  
Finally, continue research at a cellular level to promote evidence based research outcomes.  
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